Trials / Completed
CompletedNCT00494091
Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma
Phase 2, Non Randomized, Open Label Study Of Temsirolimus (CCI-779) In Subjects With Advanced Renal Cell Carcinoma (RCC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 82 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the safety, efficacy and pharmacokinetics of temsirolimus in Asian patients with advanced renal cell carcinoma. The trial is only being conducted in Japan, Korea, and China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Temsirolimus (CCI-779) | 20 mg/m2 IV TEMSR weekly (Japan, n=6) |
| DRUG | Temsirolimus (CCI-779) | 25 mg IV TEMSR weekly (all other pts) |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2011-05-01
- Completion
- 2012-03-01
- First posted
- 2007-06-29
- Last updated
- 2013-03-21
- Results posted
- 2012-07-09
Locations
24 sites across 3 countries: China, Japan, South Korea
Source: ClinicalTrials.gov record NCT00494091. Inclusion in this directory is not an endorsement.